Boosting bone healing with Trb3 and BMP-2 for osteoporosis
Tribbles homolog 3 and BMP-2 induced bone formation
This work looks at whether increasing Trb3 can improve bone formation and help BMP-2 heal bone in people with age-related osteoporosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11226287 on NIH RePORTER |
What this research studies
From a patient view, researchers are exploring ways to shift bone marrow stem cells away from making fat and back toward building bone, which is a problem in aging and osteoporosis. In the lab they will combine Trb3 (a protein they found helps bone formation) with BMP-2, a strong bone-healing factor, and test delivery methods to reduce side effects and unwanted fat formation. The team will use cell models and animal models that mimic postmenopausal osteoporosis to see whether Trb3 improves bone quality and the effectiveness of BMP-2. The goal is to find safer, more effective approaches to repair osteoporotic bone defects, including in the jaw and other craniofacial areas affected during dental procedures.
Who could benefit from this research
Good fit: Adults with age-related or postmenopausal osteoporosis who have bone defects or need bone reconstruction or dental procedures are the most relevant candidates for future therapies from this work.
Not a fit: People under age 21, those without osteoporosis, or patients with certain medical contraindications (such as active cancer affecting bone) are unlikely to benefit from the approaches in this project.
Why it matters
Potential benefit: If successful, this could lead to safer, more effective treatments to rebuild bone in people with osteoporosis and improve healing after dental or orthopedic procedures.
How similar studies have performed: Previous animal studies by the team showed that systemic Trb3 reversed osteoporosis in ovariectomized mice, and BMP-2 is an established bone-healing agent with known efficacy but dose-related safety concerns, so the combination is promising but still mainly at the preclinical stage.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Lee, Min — University of California Los Angeles
- Study coordinator: Lee, Min
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.